An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.

Inclusion Criteria:

• Diagnosis of at least moderate Major Depressive Disorder (MDD)

Exclusion Criteria:

• Comorbidities

Note for CA site: Only Veterans are Eligible